In multivariate analyses, high expression of LRRN4 remained a strong prognostic value for PFS (Table 1, HR = 1.797,95% CI = 1.009–3.200, p = 0.047) and OS (Table 2, HR = 1.733, 95% CI = 1.014–2.961, p = 0.044), even after adjusting for other covariates, indicating its potential prognostic value for PFS and OS in CRC patients. This evidence concerns the gene LRRN4 and colorectal carcinoma.